News
PTGX
127.16
+2.00%
2.49
How Much Upside is Left in Protagonist Therapeutics (PTGX)? Wall Street Analysts Think 37.6%
NASDAQ · 2d ago
Weekly Report: what happened at PTGX last week (1109-1113)?
Weekly Report · 2d ago
BMO Maintains Buy Rating and $190 Price Target on Protagonist Therapeutics, Citing Icotyde Potential and Pipeline Catalysts
TipRanks · 11/10 18:06
Analysts Offer Insights on Healthcare Companies: McKesson (MCK) and Protagonist Therapeutics (PTGX)
TipRanks · 11/10 15:00
Analysts Offer Insights on Healthcare Companies: InMed Pharmaceuticals (INM), Protagonist Therapeutics (PTGX) and Johnson & Johnson (JNJ)
TipRanks · 11/10 08:00
Weekly Report: what happened at PTGX last week (1102-1106)?
Weekly Report · 11/09 10:08
J&J posts late-stage trial win for plaque psoriasis pill in psoriatic arthritis
Seeking Alpha · 11/07 15:40
Protagonist Therapeutics Price Target Raised to $221.00/Share From $170.00 by HC Wainwright & Co.
Dow Jones · 11/06 20:23
Protagonist Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 11/06 20:23
HC Wainwright & Co. Maintains Buy on Protagonist Therapeutics, Raises Price Target to $221
Benzinga · 11/06 20:12
H.C. Wainwright Remains a Buy on Protagonist Therapeutics (PTGX)
TipRanks · 11/06 15:07
Barclays Sticks to Their Buy Rating for Protagonist Therapeutics (PTGX)
TipRanks · 11/06 09:11
Protagonist Therapeutics: Q3 Earnings Snapshot
Barchart · 11/05 15:22
UBS Maintains Buy Rating and $184 Price Target on PTGX, Citing Strong Commercial Potential for Mimrylo
TipRanks · 11/03 01:56
Weekly Report: what happened at PTGX last week (1026-1030)?
Weekly Report · 11/02 10:08
Noteworthy ETF Outflows: IJT, PTGX, VSAT, TGTX
NASDAQ · 10/29 14:52
Weekly Report: what happened at PTGX last week (1019-1023)?
Weekly Report · 10/26 10:08
Protagonist Therapeutics: The Opt-Out That Turned A Biotech Into A Royalty Compounder
Seeking Alpha · 10/25 03:45
Protagonist Therapeutics Is Maintained at Buy by TD Cowen
Dow Jones · 10/21 15:17
TD Cowen Maintains Buy on Protagonist Therapeutics, Raises Price Target to $160
Benzinga · 10/21 15:07
More
Webull provides a variety of real-time PTGX stock news. You can receive the latest news about Protagonist Ther through multiple platforms. This information may help you make smarter investment decisions.
About PTGX
Protagonist Therapeutics, Inc. is a biopharmaceutical company with a technology platform that enables de novo discovery of peptide therapeutics. The Company's programs fall into three therapeutic areas: inflammation and immunology (I&I), hematology, and metabolic diseases. Its clinical and pre-clinical programs address biologically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, obesity dual agonist peptide PN-458, oral small molecule hepcidin functional mimetic PN-8047, and IL-4 and amylin programs. The ICOTYDE (icotrokinra) is used for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy. Rusfertide is an investigational injectable mimetic of the natural hormone hepcidin in development for the treatment of the rare blood disorder polycythemia vera (PV).